Abstract
Paclitaxel is an antimitotic agent with demonstrated antineoplastic effect in various cancers including breast cancer. DHP107 (Liporaxel®) is an oral paclitaxel based on a novel lipid formulation approved in Korea for gastric cancer in 2016. This phase II randomized trial aimed to evaluate the efficacy and safety of DHP107 compared with IV paclitaxel (ptx).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
